mv-lasv
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04055454)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lassa virusImmunity, active
Lassa virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04055454 | Phase 1 | Sep 30, 2019 | Assign Clinical Research GmbH, Coalition for Epidemic Preparedness Innovations, Harmony Clinical Research, Themis Bioscience GmbH, University of Antwerp |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assign Clinical Research GmbH | For profit | 1 | 0 | 1 | 2019 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Harmony Clinical Research | For profit | 1 | 0 | 1 | 2019 |
| Themis Bioscience GmbH | For profit | 1 | 1 | 1 | 2019 |
| University of Antwerp | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1